Trial intelligence / Profile preview

Effect of Food and Water Volume on Enlicitide Decanoate PK in Healthy Adults

NCT06658652Phase 1Completed

Sponsor
Merck & Co.
Start
Oct 2023
Primary completion
Dec 2023
Modality
Small Molecules, Cyclic Peptides
Countries
1
01

Overview

Phase 1, randomised, open-label trial of enlicitide in hypercholesterolemia (2 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve from Time 0 to Infinity, Area Under the Concentration-Time Curve from Time 0 to 24 hours and 7 more. Started Oct 2023; status: completed.

02

Drugs

enlicitide
03

Conditions

hypercholesterolemia

Beyond the preview

Go deeper on NCT06658652.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT06658652.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call